Fount of Information

OriGene社 PD-L1 - A Promising Target for Cancer Therapies

PD-L1 - A Promising Target for Cancer Therapies

PD-L1 (programmed death ligand-1), also known as CD274, through its ligation to PD-1, can limit the activity of T cells in peripheral tissues during pathogen infection to prevent autoimmune responses. This interaction is exploited by cancer cells to evade effector T-cells and maintain immune tolerance. Thus, the PD1-PD-L1 axis has been heavily targeted and several clinical trials have received promising results.


OriGene provides extensive tools for PD1-PD-L1 related studies. Try our application validated TrueMAB antibodies today.



TP724015.jpg UM800120.jpg TA507087.jpg

PD-L1 Recombinant Protein (TP724015)


IHC-Validated Anti-PD-L1 Antibody (UM800120)


Flow Cytometry-Validated Anti-PD-L1 Antibody (TA507087)



Other tools are available for PD-L1-related research


IHC_Posicon.PNG PD-L1_Induction.PNG Signaling_Pathway.PNG



Scientists were also interested in



Custom Protein Service


Custom Antibody Service

    Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。